Amrutanjan Health Care has announced its audited financial results for the quarter and year ended March 31, 2026. The company reported a year-on-year increase in profitability, with total income for the fiscal year rising to INR 52,012.66 lakhs from INR 46,949.50 lakhs in the previous year.

Financial Performance for FY26

For the full year ended March 31, 2026, the company recorded a profit after tax of INR 5,791.78 lakhs, compared to INR 5,083.47 lakhs in the prior year. Revenue from operations grew to INR 50,255.27 lakhs, up from INR 45,181.63 lakhs in FY25. Basic earnings per share (EPS) for the year improved to INR 20.03 from INR 17.58 in the previous year. The results include exceptional items, specifically a lease rent provision of INR 760.50 lakhs and an impact of new Labour Codes amounting to INR 125.17 lakhs for the year.

The following table summarises the full-year financial performance:

Q4 Performance Highlights

For the quarter ended March 31, 2026, Amrutanjan Health Care delivered a strong operational performance. Revenue for the quarter stood at INR 14,976.81 lakhs, compared to INR 13,541.36 lakhs in the same quarter of the previous year. Profit after tax for the quarter was INR 1,619.28 lakhs versus INR 1,517.78 lakhs year-on-year. Notably, EBITDA for the quarter surged to INR 2,862.12 lakhs from INR 2,085.57 lakhs in the year-ago period, reflecting a significant improvement in operating efficiency. The EBITDA margin expanded to 19.12% from 15.40% year-on-year, underscoring improved cost management and operating leverage during the quarter.

The key Q4 metrics are presented below:

Dividend Declaration

The Board of Directors has recommended a final dividend of INR 2.90 per equity share for the financial year 2025-26. This dividend is applicable to 2,89,10,630 shares of INR 1 each fully paid up. If approved by shareholders at the Annual General Meeting, the dividend will be paid within 30 days of the meeting. An interim dividend of INR 1 per share was already paid during the quarter ended March 31, 2026.

Board Appointments and Approvals

The board approved the appointment of Mr. Ramaswami Krishnan (DIN: 08562199) as an Additional Director designated as Non-Executive Independent Director for a period of five years effective from May 8, 2026, subject to shareholder approval. The board also approved the re-appointment of Mr. Muralidharan Swayambunathan (DIN: 09198315) as Non-Executive Independent Director for a second and final term of five consecutive years from June 29, 2026, subject to shareholder approval. Additionally, the board approved the rollout of the revised Second Phase "ESOP 2" of the existing ESOP Scheme and appointed M/s. PKF Sridhar & Santhanam as Internal Auditors for the financial year 2026-2027.

Source: None/Company/INE098F01031/4402ce276dbe4e71.pdf

Amrutanjan Health Care has added 44,000 new chemists to its distribution network, marking a significant milestone in the company's retail outreach efforts. The company has set a target of reaching 100,000 chemists by September FY27, underscoring its commitment to expanding its presence across pharmacy channels in India.

Distribution Expansion Milestone

The onboarding of 44,000 new chemists represents a substantial step in Amrutanjan Health Care's strategy to deepen its reach within the pharmaceutical retail ecosystem. By targeting 100,000 chemists by September FY27, the company aims to nearly double its current chemist network, broadening access to its product portfolio for consumers nationwide.

The following table summarizes the key parameters of this distribution initiative:

Strategic Significance

Expanding the chemist network is a critical component of over-the-counter and healthcare product distribution in India, where pharmacy outlets serve as primary points of consumer access. Amrutanjan Health Care's initiative to scale its chemist partnerships to 100,000 by September FY27 highlights the company's focus on strengthening last-mile distribution and improving product availability across geographies.